Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is a global commercial-stage biopharmaceutical company developing medicines based on RNA interference (RNAi), a biological process used to silence gene expression. Its RNAi therapeutics target messenger RNA to reduce production of proteins implicated in disease. Alnylam… From the company’s description.
In fiscal 2025, Alnylam Pharmaceuticals, Inc. reported revenue of $3.71B, up 65.2% from fiscal 2024, and net income of $313.75M. Its operating margin was 13.5%, and operations generated $524.08M in cash. Over the twelve months to Jun 30, 2026, revenue was $4.80B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alnylam Pharmaceuticals, Inc. does
In the company’s own words
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is a global commercial-stage biopharmaceutical company developing medicines based on RNA interference (RNAi), a biological process used to silence gene expression. Its RNAi therapeutics target messenger RNA to reduce production of proteins implicated in disease. Alnylam sells four products directly: AMVUTTRA and ONPATTRO for transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Its collaborators commercialize Leqvio for high cholesterol and Qfitlia for hemophilia. The company’s research and development programs span rare and prevalent diseases, including investigational treatments for hypertension, Alzheimer’s disease and complement-mediated conditions. Its delivery technologies include GalNAc conjugates and lipid nanoparticles for liver delivery, as well as approaches for the central nervous system and other tissues. Alnylam has six marketed products and more than 20 clinical programs, including late-stage programs. In 2025, four products are directly commercialized by Alnylam and two by collaborators.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1178670
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alnylam Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alnylam Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Alnylam Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Alnylam Pharmaceuticals, Inc.’s debt, $154.25M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.00%, maturing 2027 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alnylam Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alnylam Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alnylam Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”